{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-016113","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2023-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.195889+00:00","generated_at":"2026-06-10T07:36:19.768802+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Verastem reports 42% ORR in FRAME study for avutometinib/defactinib in LGSOC","bullets":["Overall response rate 42% (11/26) in evaluable recurrent LGSOC patients.","ORR 58% in KRAS mutant LGSOC (7/12) vs 33% in KRAS wild-type (4/12).","Median duration of response 26.9 months; median PFS 20.0 months.","19% of patients (5/26) remained on treatment at data cutoff, minimum 17 months follow-up.","RAMP 201 Part A confirmed 45% ORR by independent review reported at ASCO 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-016113","json":"https://secwatch.observer/filing/0001558370-23-016113.json","markdown":"https://secwatch.observer/filing/0001558370-23-016113.md","text":"https://secwatch.observer/filing/0001558370-23-016113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000155837023016113/0001558370-23-016113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000155837023016113/vstm-20230928x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T07:36:19.768802+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}